Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Raw Materials (2017 - 2025)

Dexcom (DXCM) has disclosed Raw Materials for 12 consecutive years, with $257.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Raw Materials fell 21.25% to $257.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $257.6 million, a 21.25% decrease, with the full-year FY2025 number at $257.6 million, down 21.25% from a year prior.
  • Raw Materials was $257.6 million for Q4 2025 at Dexcom, down from $266.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $366.0 million in Q1 2025 to a low of $87.5 million in Q1 2021.
  • A 5-year average of $226.9 million and a median of $244.4 million in 2023 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: skyrocketed 107.73% in 2021, then fell 21.25% in 2025.
  • Dexcom's Raw Materials stood at $145.2 million in 2021, then increased by 9.5% to $159.0 million in 2022, then skyrocketed by 100.94% to $319.5 million in 2023, then increased by 2.38% to $327.1 million in 2024, then dropped by 21.25% to $257.6 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Raw Materials are $257.6 million (Q4 2025), $266.0 million (Q3 2025), and $346.1 million (Q2 2025).